Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer

Current Drug Targets

Volumn 13, Issue 13, 2012, Pages 1649-1653

  Huang, Ruby Yun Ju ^a,b   Chung, Vin Yee ^b   Thiery, Jean Paul ^b,c,d  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Epithelial mesenchymal transition; Ovarian cancer

Indexed keywords

AR42; BONE MORPHOGENETIC PROTEIN 4; CISPLATIN; COLLAGEN TYPE 1; DASATINIB; EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; HYPOCALCIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA 200C; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P70; SELUMETINIB; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ZIBOTENTAN; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN SNAI1;

ARTICLE; CANCER INVASION; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84870176548     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530044     Document Type: Article

References (51)

1. Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982; 95: 333-339.
2. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development 2012; 139: 3471-3486.
3. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
4. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
5. Thiery JP. Epithelial-mesenchymal transitions in cancer onset and progression. Bull Acad Natl Med 2009; 193: 1969-1978.
6. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
7. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012; 31(3/4): 673-687.
8. Chua KN, Poon KL, Lim J, Sim WJ, Huang RY, Thiery JP. Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. Adv Drug Deliv Rev 2011; 63: 558-567.
9. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374: 1371-1382.
10. Strauss R, Li ZY, Liu Y, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 2011; 6: e16186.
11. Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol 2012; 2: 33.
12. Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 2007; 213: 581-588.
13. Yoshihara K, Tajima A, Komata D, et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci 2009; 100: 1421-1428.
14. Huang RY, Tan TZ, Wong MK, et al. Epithelial-mesenchymal gene expression signature defines clinically relevant subtypes in epithelial ovarian cancer. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, Chicago, IL. Philadelphia, Mar 31-Apr 4, 2012: AACR; Cancer Res 2012; 72: Abstract nr 2979.
15. Kurrey NKKA, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005; 97: 155-165.
16. Rosano L, Spinella F, Di Castro V, et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005; 65: 11649-11657.
17. Rosano L, Spinella F, Di Castro V, et al. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood) 2006; 231: 1128-1131.
18. Theriault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 2007; 28: 1153-1162.
19. Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS. P70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res 2008; 68: 6524-6532.
20. Shepherd TG, Mujoomdar ML, Nachtigal MW. Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion. J Ovarian Res 2010; 3: 5.
21. Cheng JC, Leung PC. Type I collagen down-regulates E-cadherin expression by increasing PI3KCA in cancer cells. Cancer Lett 2011; 304: 107-116.
22. Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H. Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene 2012; 31: 2512-2520.
23. Ding JX, Feng YJ, Yao LQ, Yu M, Jin HY, Yin LH. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail. Gynecol Oncol 2006; 103: 623-630.
24. Park SH, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol 2008; 22: 2085-2098.
25. Comamala M, Pinard M, Theriault C, et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 2011; 104: 989-999.
26. Ponnusamy MP, Lakshmanan I, Jain M, et al. MUC4 mucininduced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 2010; 29: 5741-5754.
27. Law AY, Wong CK. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 2010; 316: 466-476.
28. Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007; 31: 277-283.
29. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27: 2059-2068.
30. Latifi A, Abubaker K, Castrechini N, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 2011; 112: 2850-2864.
31. Wintzell M, Hjerpe E, Avall-Lundqvist E, Shoshan M. Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer 2012; 12: 359.
32. Rosano L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17: 2350-2360.
33. Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012; 12: 91.
34. Helleman J, Smid M, Jansen MP, van der Burg MEL, Berns EM. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 2010; 117: 170-176.
35. Marchini S, Fruscio R, Clivio L, et al. Resistance to platinumbased chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer 2012. [Epub ahead of print].
36. Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
37. Lu L, Katsaros D, Mayne ST, et al. Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis 2012. [Epub ahead of print]
38. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010; 10: 268-278.
39. Ricci F, Bernasconi S, Perego P, et al. Ovarian carcinoma tumorinitiating cells have a mesenchymal phenotype. Cell Cycle 2012; 11: 1966-1976.
40. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
41. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA. American Cancer Society, 2007.
42. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008; 58: 71-96.
43. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-428.
44. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
45. Rosano L, Spinella F, Bagnato A. The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. Am J Physiol Regul Integr Comp Physiol 2010; 299: R395-R404.
46. ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients with Advanced Ovarian Cancer. Available at:http://clinicaltrials.gov/ct2/show/study/NCT00929162. Accessed September 17, 2012.
47. Chua KN, Sim WJ, Racine V, Lee SY, Goh BC, Thiery JP. A cellbased small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS One 2012; 7: e33183.
48. Twu C, Han ES. Clinical utility of targeted treatments in the management of epithelial ovarian cancer. Biologics 2012; 6: 233-244.
49. Schilder RJ, Brady WE, Lankes HA, et al. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012; 127: 70-74.
50. Balch C, Naegeli K, Nam S, et al. A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells. Cancer Biol Ther 2012; 13: 681-693.
51. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009; 8: 1055-1066.